Figure 1.

Potential evolution of HIV-1 following therapy of previously treatment-naïve individuals with integrase inhibitors. In rare cases, the emergence of resistance mutations in patients treated with raltegravir or elvitegravir can lead to virological failure (left). Virological failure with resistance mutations in treatment-naïve patients treated with dolutegravir has not been reported (right).

Wainberg et al. BMC Medicine 2013 11:249   doi:10.1186/1741-7015-11-249
Download authors' original image